NICE recommends approval of Saxenda in obesity.- Novo Nordisk

NICE has recommended the use of Saxenda (liraglutide), from Novo Nordisk, for treating obesity. Saxenda will be offered to adults with non-diabetic hyperglycaemia who have a body mass index of at least 35kg per m2 and have a high risk of CV disease due to risk factors including high blood pressure or high cholesterol levels. Pre-filled injection pens will be prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service. In January 2020, NICE was not able to recommend the therapy as its cost-effectiveness estimate was highly uncertain and potentially much higher than that considered a cost-effective use of NHS resources. The draft guidance states that Saxenda treatment should be discontinued if at least 5% body weight has not been lost after 12 weeks on the full dose. In addition, it recommends that treatment for all patients will halt after two years.